Scéil(TM) : A New Offering for the General Public to Turn Adult Cells into Stem Cells and Store Them

Regulatory News :

The Cellectis Group (Paris:ALCLS) (Alternext: ALCLS) announced today that it is launching Scéil™, an offering for the general public that involves storing induced pluripotent stem cells (iPS) generated from a skin sample so that people can benefit, if needed, from future regenerative medicine treatments as soon as they become available.

Cellectis is a biotechnology industry group with 13 years’ experience in genome engineering and stem cells. It has a strong background in handling induced pluripotent stem cells on a large scale up through their maturation and differentiation into functional cell types.

The Group has developed wide-reaching projects based on iPS cells, including the iPS Engineering Hub, a service that helps match new drugs to patient needs. Regenerative medicine is another area of development for the Group. One ongoing project, in partnership with worldwide diabetes market leader Novo Nordisk, is focused on developing a treatment for type 1 diabetes using engineered stem cells. Cellectis has also been working since 2010 with the CiRA laboratory, run by Pr Shinya Yamanaka, winner of the 2012 Nobel prize in medicine for his work on induced pluripotent stem cells.

Scéil™ is part of the Group’s strategic focus on therapeutics. While not itself a therapeutics solution, Scéil™ naturally complements the Group’s offering in this area.

Scéil™ will initially be marketed by a new wholly owned subsidiary of Cellectis SA, Scéil Private Limited, in Singapore. Another Scéil subsidiary is being set up in Dubai. These locations accord with existing national laws and regulatory frameworks.

In a meeting with US press at which Scéil™ was unveiled, André Choulika announced, "We are proud to be the first in the world to make the major scientific breakthrough of iPS cell technology available to the public. Scéil™ represents a real economic opportunity, one of the many steps forward to come in regenerative medicine.”

About Cellectis
Founded in France in 1999, the Cellectis Group bases its work on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Cellectis was co-founded by André Choulika, its Chairman and CEO, and is now one of the world’s top companies in the field of genome engineering, with revenue of $27 million in 2012. Leading the field of pluripotent stem cells, Cellectis has developed expertise in drug discovery, toxicity testing, and regenerative medicine. Cellectis has a solid background in the large-scale handling of stem cells up until their maturation and differentiation into functional cell types. We employ a workforce of 230 people at 5 sites worldwide: New Brighton (Minnesota) & Cambridge (Massachusetts) in the United States, Gothenburg in Sweden, and Paris & Evry in France. The Group has signed more than 100 industry agreements with pharmaceutical, agrochemical, and biotechnology companies. Our clients and partners include University College London (UCL), the National Institutes of Health (NIH), Novo Nordisk, the Center for iPS Cell Research and Application (CiRA) of Kyoto University, AFM, Novartis, BASF, Bayer, and Limagrain.
Since 2007, Cellectis has been listed on the NYSE Euronext Alternext market (code: ALCLS) in Paris.
For more information, visit our website: www.cellectis.com.

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country.